Hematology · Pharmacology · Coagulation cascade · Platelets
Three stages. Three drug categories. One rule that unlocks every question on this topic.
Start learning ↓The Hook
A patient is bleeding after surgery. She is on aspirin + clopidogrel. The surgeon says "we need to stop this bleeding." Where in the cascade did her drugs act?
A 58-year-old woman on dual antiplatelet therapy (aspirin + clopidogrel) is having a knee replacement. She stopped her meds 5 days ago. Intraoperatively she has unexpected oozing. Her PTT is normal, PT is normal. What does this pattern tell you?
Stage 1 (platelet plug): anti-platelet drugs live here. Stage 2 (clotting factors): heparin, warfarin, DOACs. Stage 3 (fibrinolysis or rescue): hemostatic agents. Normal PT/PTT with unexpected bleeding = think platelets first.
Stage 1 · Platelet Plug
These drugs attack the platelet plug, not the clotting factors. PT and PTT stay normal. That is why they are so sneaky on a board question.
Platelet activation pathways: 3 drug targets, 1 final common receptor
Aspirin (ASA)
Irreversible COX-1 Inhibitor
Permanently acetylates COX-1Cyclooxygenase-1: converts arachidonic acid into TXA2, the "call to arms" signal that recruits more platelets. ASA irreversibly acetylates it, unlike NSAIDs which bind reversibly. inside the platelet. No COX-1 means no TXA2. No TXA2 means platelets can't amplify aggregation. Since mature platelets have no nucleus, they cannot synthesize new COX-1, the block lasts the platelet's entire 10-day life~10 days = platelet lifespan. ~10% of platelets replaced daily. Stop ASA 7-10 days before surgery. At day 5: ~50% new functional platelets, borderline. At day 7+: usually adequate for hemostasis..
Memory Hook
ASA is the scorched earth drug. It doesn't just block TXA2, it murders the enzyme permanently. Every platelet that was alive when you took that aspirin is broken forever. New platelets are being born every day (about 10% of your stock daily), so after 10 days you're fully reset. Board favorite: "how long until platelet function returns after stopping aspirin?" → 7-10 days (platelet lifespan).
Clopidogrel / Ticagrelor / Prasugrel
P2Y12 ADP Receptor Blockers (Thienopyridines and other)
Block the P2Y12 receptor, ADP's receptor on platelets. ADP is the signal platelets use to recruit their friends. Clopidogrel and prasugrel are irreversible (prodrugs needing CYP activation). Ticagrelor is reversible and doesn't need CYP.
GpIIb/IIIa Inhibitors
Final Common Pathway Blockers · IV only
GpIIb/IIIa is the last receptor needed for platelet aggregation, fibrinogen crosslinks platelets through it. Block this and the plug literally cannot form, regardless of TXA2 or ADP levels upstream.
"Patient on clopidogrel has a normal PTT and normal PT, safe to skip bridging anticoagulation for surgery?" No. PTT and PT measure clotting factors, not platelet function. Clopidogrel patients have perfectly normal PT/PTT and still bleed because their platelet plug is broken. The test that measures platelet function is PFA-100 or platelet aggregation studies, not routinely ordered, which is why surgeons ask about medications directly.
Quick check: A patient takes clopidogrel daily. He needs a coronary artery bypass. The surgeon wants to wait before operating. How long should you wait to restore adequate platelet function?
Stage 2 · Clotting Factors
These drugs work downstream of platelets, inside the coagulation cascade itself. The cascade splits into intrinsic (PTT) and extrinsic (PT) before merging at Factor X. Know which drug hits which arm.
Coagulation cascade: intrinsic, extrinsic, common pathways with drug targets labeled
Warfarin (Coumadin)
Vitamin K Epoxide Reductase Inhibitor · Oral
Blocks vitamin K recyclingWarfarin blocks VKORC1 (Vit K epoxide reductase). Without recycled Vit K, Factors II/VII/IX/X can't be gamma-carboxylated. They're made but dysfunctional, like a car with no spark plugs.. Without active vitamin K, the liver can't gamma-carboxylate the Vitamin K-dependent factors, they're synthesized but non-functional. Hits: II, VII, IX, X (pro-coagulant) and Protein C, Protein S (anti-coagulant). The extrinsic pathway is what warfarin most visibly disrupts because Factor VII has the shortest half-lifeFactor VII half-life = 4-6 hours. This is why PT/INR rises first when starting warfarin, before any true anticoagulation. Factor II (prothrombin) has the longest half-life (~60h), so full anticoagulation takes 4-5 days..
Memory Hook
The hook: Warfarin hits II, VII, IX, X plus Protein C and S. Say it out loud: "C, S, Two, Seven, Nine, Ten." That's all six. The trap is that Protein C has the shortest half-life (~6h) of the bunch, so when you start warfarin cold you knock out the anticoagulant brake BEFORE the pro-coagulant engine slows down. Result: transient hypercoagulable state, skin necrosis. This is why warfarin always needs a heparin bridge at the start.
Day 3 of warfarin, the patient develops painful necrotic skin lesions on fatty areas (thighs, breasts, abdomen). Why? Protein C drops first (short half-life, 6h), but Factors II, IX, X are still functional. You've killed the anticoagulant protein before the pro-coagulant factors fall. The result: transient hypercoagulability → small vessel thrombosis in fat-rich skin. Fix: always bridge with heparin for 5 days when starting warfarin. Patients with hereditary Protein C deficiency are at highest risk.
Unfractionated Heparin (UFH)
Antithrombin III (ATIII) Cofactor · IV or SQ
Binds antithrombin IIIATIII = endogenous anticoagulant. Normally slow. Heparin docks onto ATIII and turbocharges it 1000x. Think of ATIII as a sleepy security guard and heparin as a triple espresso shot. and amplifies its activity 1000x. ATIII then destroys Thrombin (IIa) and Factors Xa, IXa, XIa, XIIa. UFH hits both pathways but especially intrinsic. Does not dissolve existing clots, just prevents new ones.
LMWH, Enoxaparin (Lovenox)
Low Molecular Weight Heparin · SQ only
Same ATIII mechanism but smaller molecule. Preferentially blocks Factor Xa over Thrombin (Xa:IIa ratio ~3:1). More predictable kinetics = fixed weight-based dosing without routine monitoring.
Platelet drops 50%+ at day 5-10 of heparin, and the patient develops a NEW clot (DVT, PE, limb ischemia). Counterintuitive: fewer platelets + more clotting. Why? IgG antibodies form against the heparin-PF4 complex → antibodies activate platelets massively. Stop ALL heparin (including line flushes, LMWH, cross-reactive). Start argatroban (hepatic clearance) or bivalirudin. Do NOT start warfarin yet (Protein C will drop first → more clotting). Do NOT transfuse platelets (adds fuel). The common wrong answer is "switch to LMWH", LMWH still activates HIT antibodies.
Direct Oral Anticoagulants (DOACs)
Direct Thrombin Inhibitors (IIa) and Direct Factor Xa Inhibitors
Skip the ATIII middleman entirely, bind directly to the active site of their target. DOACs do not need monitoring (except anti-Xa for Xa inhibitors in specific cases). Predictable dosing by weight and renal function.
Memory Hook
Renal ranking: Dabigatran (80% renal) > Rivaroxaban (35%) > Apixaban (27%). Mnemonic: "Dabigatran Dies by the Kidney, Apixaban is Alright." If your patient has a creatinine that's climbing, check the drug, if it's dabigatran, that is the most dangerous one to keep. Edoxaban: paradox, don't use if CrCl >95 (too-fast clearance means subtherapeutic levels).
A 72-year-old man with A-fib and CKD stage 3b (eGFR 38) needs anticoagulation. Which DOAC is safest?
Stage 3 · Reversal and Rescue
When the patient is bleeding and you need to act. These don't anticoagulate, they reverse, replenish, or protect existing clots.
Fibrinolysis pathway: TXA blocks plasminogen binding at lysine sites to preserve clot
Tranexamic Acid (TXA)
Antifibrinolytic, Lysine Analogue
Blocks the lysine binding site on plasminogen → plasmin can't form → fibrin clot isn't dissolved. It doesn't make new clot. It just protects existing clot from being eaten. Works downstream of everything.
Fresh Frozen Plasma (FFP)
All Clotting Factors (I-XIII)
Every clotting factor, Protein C, Protein S, all of it. The "shotgun" approach to coagulopathy.
Cryoprecipitate
Concentrated Fibrinogen + Factor VIII + vWF + XIII
The cold-precipitated fraction of FFP. Highly concentrated in the factors that deplete fastest in massive bleeding: fibrinogen is the first to run dry in DIC and massive transfusion.
Protamine Sulfate
Heparin Reversal, Electrostatic Binding
Positively charged protein that neutralizes negatively charged heparin by direct ionic binding. Instantly inactive the heparin-ATIII complex.
DDAVP (Desmopressin)
V2 Receptor Agonist, Releases Stored vWF and Factor VIII
Triggers Weibel-Palade bodiesEndothelial storage granules packed with vWF and Factor VIII. DDAVP (V2 agonist) causes exocytosis. Boosts levels 3-5x for 6-8 hours. Tachyphylaxis after 2-3 doses as stores deplete. Useless in severe hemophilia A (no stored Factor VIII to release). to dump stored vWF and Factor VIII into circulation. Temporarily boosts platelet adhesion and intrinsic pathway activity.
Massive transfusion, fibrinogen is 65 mg/dL, patient is bleeding from every surface. The answer is cryoprecipitate, not FFP. Why? To raise fibrinogen significantly with FFP you'd need enormous volumes (liters). Each unit of cryo has ~250 mg of fibrinogen, highly concentrated. FFP has everything but dilute. If the question specifically says low fibrinogen in an actively bleeding patient, it's cryo. If the question says "needs reversal of all coagulation factors," it's FFP.
Putting It Together
Know your drug, know your lab. This is the question format that trips people up most in clinical practice.
| Drug | Trace It | Lab to Monitor | Reversal Agent |
|---|---|---|---|
| ASA | Irreversible COX-1 inhibition | None (PFA-100 rarely ordered) | Platelet transfusion / wait 10 days |
| Clopidogrel | Irreversible P2Y12 block | None | Platelet transfusion / wait 5-7 days |
| Heparin (UFH) | ATIII cofactor → blocks IIa, Xa, IXa, XIa, XIIa | PTT (goal 2-2.5x normal) | Protamine sulfate (1 mg / 100 U) |
| LMWH (Enoxaparin) | ATIII cofactor → blocks Xa >> IIa | Anti-Xa level (if needed) | Protamine (~60% effective) |
| Warfarin | Blocks Vit K recycling → II, VII, IX, X, Protein C/S | PT/INR (goal 2-3) | Vit K + FFP / 4-factor PCC |
| Dabigatran | Direct Thrombin inhibitor (IIa) | None routinely | Idarucizumab (Praxbind) |
| Rivaroxaban / Apixaban | Direct Factor Xa inhibitor | None routinely | Andexanet alfa / 4-factor PCC |
| Argatroban / Bivalirudin | IV direct thrombin inhibitor (HIT use) | PTT | No specific antidote, short half-life, stop infusion |
PTT = intrinsic + common pathway → measures heparin and DTIs.
PT/INR = extrinsic + common pathway → measures warfarin and liver failure.
Both elevated = common pathway issue (Factor X, V, II deficiency, DIC, severe liver failure).
Both normal with bleeding = platelet problem, vWD, or Factor XIII deficiency.
Reversal Reference
UFH
Protamine sulfate
1 mg per 100 units UFH. Works in minutes. 100% reversal.
LMWH
Protamine sulfate (partial)
~60% reversal. No full antidote. Monitor anti-Xa if needed.
Warfarin
Vitamin K + FFP or 4-factor PCC
Vit K: 6-24h. PCC: fastest for active bleed. FFP: large volume.
Dabigatran
Idarucizumab (Praxbind)
Humanized Ab fragment. Complete reversal in <5 min. FDA 2015.
Rivaroxaban / Apixaban
Andexanet alfa (AndexXa)
Decoy Xa protein. 4-factor PCC also used off-label.
ASA / Clopidogrel
Platelet transfusion
No pharmacologic antidote. Wait 5-10 days or transfuse.
Drug Villains
Tap each card to flip it. Front: who they are. Back: how they work and how to stop them.
Heparin (UFH)
ATIII Cofactor · IV or SQ
Target: Amplifies ATIII 1000x → destroys Thrombin (IIa) + Xa, IXa, XIa, XIIa. Monitors with PTT.
Tap to reveal MOA + reversal
Trace It
Binds ATIII and turbocharges it 1000x. ATIII then serine-protease-kills thrombin and multiple upstream factors. UFH is big enough to bridge ATIII and thrombin simultaneously. Does NOT dissolve existing clot.
Board Trap
HIT Type II: platelet drop at day 5-10 + paradoxical NEW clot. IgG antibodies against heparin-PF4 complex. STOP all heparin. Switch to argatroban.
Reversal: Protamine sulfate (1 mg per 100 units UFH)
Warfarin
Vitamin K Antagonist · Oral
Target: Blocks Vit K recycling → non-functional II, VII, IX, X + Protein C/S. Monitors with PT/INR.
Tap to reveal MOA + reversal
Trace It
Blocks VKORC1 (Vit K epoxide reductase). Without recycled Vit K, the liver makes non-functional clotting factors. Onset 2-5 days because existing factors must clear first.
Skin Necrosis Risk
Protein C drops first (6h half-life) before pro-coagulant factors clear → transient hypercoagulability → skin necrosis day 3. Always bridge with heparin for 5 days.
Reversal: Vit K + FFP or 4-factor PCC for active bleeding
Dabigatran
Direct Thrombin Inhibitor · Oral
Target: Directly blocks Thrombin (IIa) active site. No ATIII middleman. 80% renally cleared = dangerous in CKD.
Tap to reveal MOA + reversal
Trace It
Directly occupies the thrombin active site. Predictable pharmacokinetics. No routine monitoring needed. Elevates PTT slightly but not used for monitoring.
Key Weakness
80% renal clearance. CKD stage 3+ = drug accumulates. Cannot use with mechanical heart valves or in pregnancy. Only DOAC with a dialyzable molecule.
Reversal: Idarucizumab (Praxbind) - humanized Ab fragment
Apixaban / Rivaroxaban
Direct Factor Xa Inhibitors · Oral
Target: Occupy Xa active site directly. Apixaban = safest in CKD (27% renal). Rivaroxaban = 35% renal, once daily.
Tap to reveal MOA + reversal
Trace It
Bind the active site of Factor Xa directly, preventing conversion of prothrombin to thrombin. No ATIII needed. No routine monitoring. Fixed dosing.
Edoxaban Paradox
Do NOT use edoxaban if CrCl >95 mL/min. Too fast clearance = subtherapeutic levels. Counter-intuitive board trap: "good kidneys contraindicate edoxaban."
Reversal: Andexanet alfa (decoy Xa) or 4-factor PCC off-label
Aspirin (ASA)
Irreversible COX-1 Inhibitor
Target: Permanently acetylates COX-1 → no TXA2 → platelets can't amplify aggregation. PT/PTT both NORMAL.
Tap to reveal MOA + reversal
Trace It
Covalently acetylates serine residue on COX-1. Since platelets have no nucleus, they can't regenerate COX-1. Block lasts the platelet's entire life (~10 days). ~10% platelet turnover daily.
Surgery Rule
Stop ASA 7-10 days before elective surgery. At day 5: ~50% platelet function restored. At day 7: ~70%, adequate for most surgery. Irreversible = no pharmacologic antidote.
Reversal: Platelet transfusion only (wait 7-10 days)
Clopidogrel
Irreversible P2Y12 Blocker (Prodrug)
Target: Blocks P2Y12 (ADP receptor) on platelets. Requires CYP2C19 activation. PT/PTT both NORMAL.
Tap to reveal MOA + reversal
Trace It
Prodrug activated by CYP2C19. Active metabolite irreversibly binds P2Y12, blocking ADP-mediated platelet recruitment. CYP2C19 poor metabolizers get NO antiplatelet effect (genetic trap!).
CABG Rule
Hold clopidogrel 5-7 days before CABG. At day 5: enough new P2Y12-virgin platelets for adequate hemostasis. Ticagrelor (reversible) only needs 3-5 days washout.
Reversal: Platelet transfusion (wait 5-7 days)
Decision Tree
The algorithm clinical medicine loves to hide in a 4-line stem.
Clinical Images
Structures and clinical context for key anticoagulant drugs.
Pick the indication. Follow the branches. The right drug follows from the patient's situation, not from memorization.
Final Check
No time limit. No pressure. Just see how solid your understanding is.
clinical Walkthrough
Original clinical vignettes. Shuffled, never-repeat, full explanations for every choice.
Keep Going
